Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
885.5 USD | -0.58% | -1.32% | +0.77% |
06:25pm | Regeneron Faces Q1 Seasonality Despite Eylea HD Launch, Oppenheimer Says | MT |
02:45pm | Oppenheimer Adjusts Price Target on Regeneron Pharmaceuticals to $1,175 From $1,125 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.80% | 95.71B | |
-2.02% | 103B | |
+1.69% | 22.02B | |
-17.06% | 20.9B | |
-9.30% | 17.85B | |
-41.01% | 16.21B | |
-15.03% | 15.52B | |
+3.25% | 13.86B | |
+34.84% | 12.04B | |
-25.24% | 8.08B |
- Stock Market
- Equities
- REGN Stock
- News Regeneron Pharmaceuticals, Inc.
- Regeneron Beats Fourth-Quarter Views, Expects No COVID-19 Drug's US Sales in First Half